BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 26528756)

  • 1. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis.
    Chang YW; Hsieh PW; Chang YT; Lu MH; Huang TF; Chong KY; Liao HR; Cheng JC; Tseng CP
    Oncotarget; 2015 Dec; 6(40):42733-48. PubMed ID: 26528756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis.
    Sasaki T; Shirai T; Tsukiji N; Otake S; Tamura S; Ichikawa J; Osada M; Satoh K; Ozaki Y; Suzuki-Inoue K
    J Thromb Haemost; 2018 May; 16(5):960-972. PubMed ID: 29488681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis.
    Sekiguchi T; Takemoto A; Takagi S; Takatori K; Sato S; Takami M; Fujita N
    Oncotarget; 2016 Jan; 7(4):3934-46. PubMed ID: 26684030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polysaccharide-containing fraction from Artemisia argyi inhibits tumor cell-induced platelet aggregation by blocking interaction of podoplanin with C-type lectin-like receptor 2.
    Tseng CP; Huang YL; Chang YW; Liao HR; Chen YL; Hsieh PW
    J Food Drug Anal; 2020 Jan; 28(1):115-123. PubMed ID: 31883599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis.
    Sheng M; Sun R; Fu J; Lu G
    BMC Cancer; 2024 Apr; 24(1):399. PubMed ID: 38561690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of polypeptides derived from a snake venom C-type lectin, aggretin, on tumor cell-induced platelet aggregation.
    Chang CH; Chung CH; Hsu CC; Peng HC; Huang TF
    J Thromb Haemost; 2014 Apr; 12(4):540-9. PubMed ID: 24479713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides.
    Delierneux C; Donis N; Servais L; Wéra O; Lecut C; Vandereyken M; Musumeci L; Rahmouni S; Schneider J; Eble JA; Lancellotti P; Oury C
    J Thromb Haemost; 2017 May; 15(5):983-997. PubMed ID: 28296036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Identification of the novel platelet activation receptor CLEC-2 and Its pathological and physiological roles].
    Suzuki Inoue K; Inoue O; Ozaki Y
    Rinsho Byori; 2010 Dec; 58(12):1193-202. PubMed ID: 21348239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.
    Xu M; Wang X; Pan Y; Zhao X; Yan B; Ruan C; Xia L; Zhao Y
    BMC Cancer; 2019 Jun; 19(1):599. PubMed ID: 31208371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cobalt hematoporphyrin inhibits CLEC-2-podoplanin interaction, tumor metastasis, and arterial/venous thrombosis in mice.
    Tsukiji N; Osada M; Sasaki T; Shirai T; Satoh K; Inoue O; Umetani N; Mochizuki C; Saito T; Kojima S; Shinmori H; Ozaki Y; Suzuki-Inoue K
    Blood Adv; 2018 Sep; 2(17):2214-2225. PubMed ID: 30190281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.
    Kato Y; Kaneko MK; Kunita A; Ito H; Kameyama A; Ogasawara S; Matsuura N; Hasegawa Y; Suzuki-Inoue K; Inoue O; Ozaki Y; Narimatsu H
    Cancer Sci; 2008 Jan; 99(1):54-61. PubMed ID: 17944973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diphenyl-tetrazol-propanamide Derivatives Act as Dual-Specific Antagonists of Platelet CLEC-2 and Glycoprotein VI.
    Watanabe N; Shinozaki Y; Ogiwara S; Miyagasako R; Sasaki A; Kato J; Suzuki Y; Fukunishi N; Okada Y; Saito T; Iida Y; Higashiseto M; Masuda H; Nagata E; Gotoh K; Amino M; Tsuji T; Morita S; Nakagawa Y; Hirayama N; Inokuchi S
    Thromb Haemost; 2024 Mar; 124(3):203-222. PubMed ID: 37967855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.
    Ukaji T; Takemoto A; Shibata H; Kakino M; Takagi S; Katayama R; Fujita N
    Cancer Sci; 2021 Jun; 112(6):2299-2313. PubMed ID: 33735501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells.
    Suzuki-Inoue K; Kato Y; Inoue O; Kaneko MK; Mishima K; Yatomi Y; Yamazaki Y; Narimatsu H; Ozaki Y
    J Biol Chem; 2007 Sep; 282(36):25993-6001. PubMed ID: 17616532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet CLEC2-Podoplanin Axis as a Promising Target for Oral Cancer Treatment.
    Hwang BO; Park SY; Cho ES; Zhang X; Lee SK; Ahn HJ; Chun KS; Chung WY; Song NY
    Front Immunol; 2021; 12():807600. PubMed ID: 34987523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin.
    Suzuki-Inoue K
    Blood; 2019 Nov; 134(22):1912-1918. PubMed ID: 31778548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-type lectin-like receptor-2 (CLEC-2) is a key regulator of kappa-carrageenan-induced tail thrombosis model in mice.
    Yokomori R; Shirai T; Tsukiji N; Oishi S; Sasaki T; Takano K; Suzuki-Inoue K
    Platelets; 2023 Dec; 34(1):2281941. PubMed ID: 38010137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential in vivo roles of the platelet activation receptor CLEC-2 in tumour metastasis, lymphangiogenesis and thrombus formation.
    Suzuki-Inoue K
    J Biochem; 2011 Aug; 150(2):127-32. PubMed ID: 21693546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular Smooth Muscle Cells Stimulate Platelets and Facilitate Thrombus Formation through Platelet CLEC-2: Implications in Atherothrombosis.
    Inoue O; Hokamura K; Shirai T; Osada M; Tsukiji N; Hatakeyama K; Umemura K; Asada Y; Suzuki-Inoue K; Ozaki Y
    PLoS One; 2015; 10(9):e0139357. PubMed ID: 26418160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation of threonine 34 in mouse podoplanin-Fc reduces CLEC-2 binding and toxicity in vivo while retaining antilymphangiogenic activity.
    Bianchi R; Fischer E; Yuen D; Ernst E; Ochsenbein AM; Chen L; Otto VI; Detmar M
    J Biol Chem; 2014 Jul; 289(30):21016-27. PubMed ID: 24907275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.